Premium
CD44s and CD44v6 expression in localized T1–T2 conventional renal cell carcinomas
Author(s) -
Daniel Laurent,
Lechevallier Eric,
Giorgi Roch,
Lindner Véronique,
De Fromont Marc,
Vieillefond Annick,
Coulange Christian,
FigarellaBranger Dominique
Publication year - 2001
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/1096-9896(2000)9999:9999<::aid-path817>3.0.co;2-h
Subject(s) - pathology , renal cell carcinoma , cell , cancer research , medicine , biology , genetics
To assess the prognostic value of CD44s and CD44v6 tumour expression for patients with T1–T2 conventional renal cell carcinomas, a retrospective immunohistochemical analysis of 95 patients was undertaken. These patients had undergone a radical nephrectomy, performed in three institutions in France between 1987 and 1993. The mean age of the patients was 62.9±10.2 years (range from 37 to 85 years) with 66.3% males. At the time of surgery, 84 patients had a T1 and 11 a T2 renal tumour. Fuhrman nuclear grading showed 44 (46.3%) tumours of grade 1, 39 (41.1%) of grade 2, and 12 (12.6%) of grade 3. The mean follow‐up period was 58.1±36.1 months. At the end of follow‐up, eight patients (8.4%) had metastatic disease and no local recurrence was seen. Immunohistochemistry showed that 26 tumours (27.4%) expressed CD44s, but none expressed CD44v6. Statistical analysis showed that CD44s expression was correlated with tumour size ( p =0.006) and Fuhrman grading ( p <10 −4 ). Among the various parameters tested for the multivariate analysis, CD44s expression correlated only with disease‐free survival ( p =0.04). It is concluded that CD44s expression, but not CD44v6, is of potential prognostic interest in patients with localized T1–T2 conventional renal cell carcinomas. Copyright © 2000 John Wiley & Sons, Ltd.